Synaptogenix (NASDAQ:TAOX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Synaptogenix to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
Profitability
This table compares Synaptogenix and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synaptogenix | -2,153.97% | -128.51% | -97.54% |
| Synaptogenix Competitors | -2,380.61% | -219.90% | -15.56% |
Earnings and Valuation
This table compares Synaptogenix and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Synaptogenix | $300,000.00 | -$28.74 million | -0.67 |
| Synaptogenix Competitors | $3.57 billion | $3.20 billion | 553.77 |
Synaptogenix’s rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings for Synaptogenix and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synaptogenix | 1 | 0 | 0 | 0 | 1.00 |
| Synaptogenix Competitors | 7776 | 13766 | 25735 | 1036 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 25.23%. Given Synaptogenix’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Synaptogenix has less favorable growth aspects than its rivals.
Volatility & Risk
Synaptogenix has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Synaptogenix’s rivals have a beta of -3.81, suggesting that their average share price is 481% less volatile than the S&P 500.
Insider & Institutional Ownership
10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Synaptogenix rivals beat Synaptogenix on 10 of the 13 factors compared.
Synaptogenix Company Profile
Synaptogenix, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. Its research has centered primarily on bryostatin-1, a drug candidate being investigated for its potential to improve synaptic function and memory. The company has historically pursued treatments for conditions including Alzheimer’s disease and Fragile X syndrome. Its development programs have been research- and clinical-stage, with no indication that it operates a broad commercial product portfolio.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
